Science

Jan 30, 2025, 13:35

Myeloma Paper of the Day, January 30th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) may safely induce disease remissions in relapsed, refractory myeloma without CRS or ICANS though median PFS was only 6.0 months.”

“Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma”

Authors: Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence Lum, Deborah Glass, Jee Park, Michele Donato, David Siegel, Tania Felizardo and Daniel Fowler.

More posts featuring Robert Orlowski.

Aniko Szabo Binod Dhakal cancer Daniel Fowler David Siegel Deborah Glass Jee Park Lawrence Lum Michele Donato multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Parameswaran Hari RAPA-201 Robert Orlowski Saurabh Chhabra Tania Felizardo

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25